Study of MRT-2359 with apalutamide for prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial tests a new oral drug, MRT-2359, combined with apalutamide (a standard hormone therapy) in men with a specific type of prostate cancer that has stopped responding to hormone treatment. The goal is to see if the combination can slow or stop the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old.
- You have a type of prostate cancer that no longer responds to hormone therapy (castration-resistant) and has a specific change in the androgen receptor gene.
- You have had at least one prior hormone therapy (like enzalutamide or abiraterone) for your prostate cancer.
- You have not had more than one prior chemotherapy regimen (like docetaxel or cabazitaxel) for your cancer.
- You have not been treated with an AR degrader or similar drug before.
- You are willing to provide a tumor biopsy during screening.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new study drug called ACE-232 for men with advanced prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It aims to see if the drug is safe and may help slow the cancer.
This trial tests a new combination of two medicines for advanced prostate cancer that has spread and is no longer responding to current hormone therapy. The goal is to see if adding the experimental drug mevrometostat to enzalutamide helps control the cancer better.
This trial tests a new radioactive drug designed to target and destroy prostate cancer cells. It is for men whose cancer has continued to grow despite hormone therapy and other treatments like enzalutamide or abiraterone.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This trial looks at combining hormone therapy with either chemotherapy (docetaxel), a targeted pill (like abiraterone or enzalutamide), or radiation to the prostate tumor for men whose prostate cancer has spread but is still sensitive to hormones. The goal is to see which approach works best for controlling the cancer.
This trial tests an experimental drug, GLR2037, for men with advanced prostate cancer that has spread to the bones or soft tissue and has progressed despite prior treatments. The drug may help slow the cancer's growth.
Hear when a new Castration-resistant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.